Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | terminated | Phase 1 / Phase 2 | 15 | PrECOG, LLC.OTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02937675 | A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 28 | Effector TherapeuticsINDUSTRY | 1 | Nov 2, 2020 |
| clinicaltrials |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Oct 27, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01498445 | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | terminated | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | terminated | Phase 1 | 9 | IRCCS San RaffaeleOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 7 | Oct 1, 2020 | clinicaltrials |
| NCT02266147 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 29 | Dynavax Technologies CorporationINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | terminated | Phase 1 / Phase 2 | 25 | The Lymphoma Academic Research OrganisationOTHER | 2 | Sep 2, 2020 | clinicaltrials |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | terminated | Phase 1 | 11 | Agios Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis | terminated | Phase 1 | 3 | Tufts Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | University of California, San DiegoOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT00093704 | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | terminated | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02781467 | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 10 | Celularity IncorporatedINDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 65 | AmgenINDUSTRY | 2 | Jul 13, 2020 | clinicaltrials |
| NCT01551043 | Allo CART-19 Protocol | terminated | Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02985554 | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies | terminated | Phase 1 | 3 | University of ChicagoOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 5 | Mayo ClinicOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT01615042 | Phase I Study of Lenalidomide in Patients With Acute Leukemia | terminated | Phase 1 | 6 | Mehrdad Abedi, MDOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | terminated | Phase 1 | 34 | PfizerINDUSTRY | 3 | Apr 24, 2020 | clinicaltrials |
| NCT01636609 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Cogent Biosciences, Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | terminated | Phase 1 | 17 | C. Babis AndreadisOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | terminated | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02082626 | Study of Eribulin in Children With Cancer to Determine Safety(ERIBULIN) | terminated | Phase 1 | 3 | University of OklahomaOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults(Japanese AML) | terminated | Phase 1 | 9 | Gilead SciencesINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | terminated | Phase 1 | 23 | Polaris GroupINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | terminated | Phase 1 | 2 | Yale UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 35 | ADC Therapeutics S.A.INDUSTRY | 1 | Feb 26, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | terminated | Phase 1 / Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 | 1 | Northwestern UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 3, 2020source: clinicaltrials